Marc Peeters

Wild-Type <i>KRAS</i> Is Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer

Rafael G. Amado, Michael Wolf, Marc Peeters et al. · Journal of Clinical Oncology · 2008 · 3.2K citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Open-Label Phase III Trial of Panitumumab Plus Best Supportive Care Compared With Best Supportive Care Alone in Patients With Chemotherapy-Refractory Metastatic Colorectal Cancer

Eric Van Cutsem, Marc Peeters, Salvatore Siena et al. · Journal of Clinical Oncology · 2007 · 2K citations

Medicine, Oncology, Pharmacology +14

Randomized Trial of TAS-102 for Refractory Metastatic Colorectal Cancer

Robert J. Mayer, Eric Van Cutsem, Alfredo Falcone et al. · New England Journal of Medicine · 2015 · 1.4K citations · Full text

Medicine, Pharmacology, Pharmacotherapy +11

Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study

Marianne Pavel, John D. Hainsworth, Éric Baudin et al. · The Lancet · 2011 · 1.1K citations

Medicine, Oncology, Pharmacotherapy +16

Randomized Phase III Study of Panitumumab With Fluorouracil, Leucovorin, and Irinotecan (FOLFIRI) Compared With FOLFIRI Alone As Second-Line Treatment in Patients With Metastatic Colorectal Cancer

Marc Peeters, Timothy Price, Andrés Cervantes et al. · Journal of Clinical Oncology · 2010 · 1K citations

Medicine, Oncology, Pharmacology +15